{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DL3&page=3",
    "query": {
      "intervention": "DL3",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 85,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DL3&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DL3&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T12:38:29.554Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00892190",
      "title": "Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "dasatinib (SPRYCEL)",
          "type": "DRUG"
        },
        {
          "name": "all trans retinoic acid (VESANOID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2011-04",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00892190"
    },
    {
      "nct_id": "NCT01033032",
      "title": "Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Amrubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 78,
      "start_date": "2009-12",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 16,
      "location_summary": "Jonesboro, Arkansas • Fort Myers, Florida • Gainesville, Georgia + 11 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01033032"
    },
    {
      "nct_id": "NCT05631704",
      "title": "A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH4524184",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 84,
      "start_date": "2022-12-02",
      "completion_date": "2023-07-27",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05631704"
    },
    {
      "nct_id": "NCT03813407",
      "title": "An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperkalaemia"
      ],
      "interventions": [
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 140,
      "start_date": "2019-04-02",
      "completion_date": "2030-02-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03813407"
    },
    {
      "nct_id": "NCT02045940",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cachexia"
      ],
      "interventions": [
        {
          "name": "GSK2881078",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 99,
      "start_date": "2014-01-20",
      "completion_date": "2015-03-26",
      "has_results": false,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 2,
      "location_summary": "Overland Park, Kansas • Baltimore, Maryland",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045940"
    },
    {
      "nct_id": "NCT01838551",
      "title": "Treatment for Endogenous Cushing's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endogenous Cushing's Syndrome"
      ],
      "interventions": [
        {
          "name": "Levoketoconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cortendo AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2014-08",
      "completion_date": "2018-11",
      "has_results": true,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01838551"
    },
    {
      "nct_id": "NCT01113502",
      "title": "Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2010-06",
      "completion_date": "2015-11-10",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01113502"
    },
    {
      "nct_id": "NCT03107988",
      "title": "NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim/pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Year to 99 Years"
      },
      "enrollment_count": 65,
      "start_date": "2017-09-05",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03107988"
    },
    {
      "nct_id": "NCT03332667",
      "title": "MIBG With Dinutuximab +/- Vorinostat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "131I-MIBG",
          "type": "RADIATION"
        },
        {
          "name": "Dinutuximab",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "DRUG"
        },
        {
          "name": "Potassium Iodide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 45,
      "start_date": "2018-09-12",
      "completion_date": "2024-02-23",
      "has_results": true,
      "last_update_posted_date": "2025-04-16",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332667"
    },
    {
      "nct_id": "NCT02187133",
      "title": "Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2015-05-05",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-10T12:38:29.554Z",
      "location_count": 3,
      "location_summary": "Davis, California • San Diego, California • San Francisco, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02187133"
    }
  ]
}